Segment Data

12 Months Ended

Dec. 31, 2020

Segment Data

Segment Data

14. Segment Data

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company’s reportable segments sales and net income consisted of:

	Year Ended
(in thousands)	2020		2019
Revenue from external customers
Human Health	$	9,309	$	5,673
Animal Health		76		102
Consolidated Totals	$	9,385	$	5,775
Segment net loss
Human Health	$	(9,779)	$	(19,263)
Animal Health		(24,030)		(19,276)
Consolidated Totals	$	(33,809)	$	(38,539)

The Company’s reportable segments assets consisted of the following:

	December 31,
(in thousands)	2020		2019
Segment assets
Human Health	$	34,201	$	32,432
Animal Health		79,760		68,169
Total	$	113,961	$	100,601

The reconciliation of segments assets to the consolidated assets is as follows:

	December 31,
(in thousands)	2020		2019
Total assets for reportable segments	$	113,961	$	100,601
Less: Investment in subsidiary		(29,241)		(29,241)
Less: Intercompany loan		(41,877)		(34,950)
Consolidated Totals	$	42,843	$	36,410